Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenFleet Therapeutics (Shanghai)'s revenue for the
six
months ended in Dec. 2025 was €5.04 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €15.75 Mil.
GenFleet Therapeutics (Shanghai)'s Revenue per Share for the
six
months ended in Dec. 2025 was €0.01.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.05.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
GenFleet Therapeutics (Shanghai) Revenue Related Terms
GenFleet Therapeutics (Shanghai) Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenFleet Therapeutics (Shanghai) Revenue Chart
GenFleet Therapeutics (Shanghai) Annual Data
Trend
Dec23
Dec24
Dec25
Revenue
9.47
13.73
15.80
GenFleet Therapeutics (Shanghai) Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Revenue
0.00
0.00
13.73
10.72
5.04
HAM:Y3L vs VRTX, REGN, RVMD: Revenue Comparison
For the Biotechnology subindustry, GenFleet Therapeutics (Shanghai)'s Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GenFleet Therapeutics (Shanghai) Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GenFleet Therapeutics (Shanghai)'s Revenue distribution charts can be found below:
* The bar in red indicates where GenFleet Therapeutics (Shanghai)'s Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €15.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a Revenue of €15.75 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on GenFleet Therapeutics (Shanghai) and its competitors.
Is GenFleet Therapeutics (Shanghai)'s Revenue too high?
GenFleet Therapeutics (Shanghai)'s current Revenue is €15.75 Mil. Overall, GenFleet Therapeutics (Shanghai) has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does GenFleet Therapeutics (Shanghai)'s Revenue compare to VRTX and REGN?
GenFleet Therapeutics (Shanghai)'s Revenue of €15.75 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. GenFleet Therapeutics (Shanghai)'s current Revenue is €15.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenFleet Therapeutics (Shanghai) stock overvalued right now?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a current Revenue of €15.75 Mil. The current Revenue is €15.75 Mil. GenFleet Therapeutics (Shanghai)'s overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For GenFleet Therapeutics (Shanghai) (HAM:Y3L), the current Revenue is €15.75 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GenFleet Therapeutics (Shanghai) Inc Company is a clinical-stage biotechnology company. The Company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment.
19GF Score
Get the complete analysis for HAM:Y3L
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:Y3L has been successfully added to your 
